Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Conmed (CNMD) over the last 16 years, with Q4 2025 value amounting to $46.3 million.

  • Conmed's Cash from Operations rose 691.54% to $46.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $170.7 million, marking a year-over-year increase of 222.86%. This contributed to the annual value of $170.7 million for FY2025, which is 222.86% up from last year.
  • Per Conmed's latest filing, its Cash from Operations stood at $46.3 million for Q4 2025, which was up 691.54% from $53.7 million recorded in Q3 2025.
  • Over the past 5 years, Conmed's Cash from Operations peaked at $56.4 million during Q4 2023, and registered a low of -$11.6 million during Q4 2022.
  • Over the past 5 years, Conmed's median Cash from Operations value was $31.5 million (recorded in 2021), while the average stood at $30.4 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first crashed by 127286.59% in 2023, then soared by 85697.95% in 2024.
  • Quarter analysis of 5 years shows Conmed's Cash from Operations stood at $33.8 million in 2021, then plummeted by 134.33% to -$11.6 million in 2022, then soared by 586.25% to $56.4 million in 2023, then fell by 23.15% to $43.3 million in 2024, then rose by 6.92% to $46.3 million in 2025.
  • Its last three reported values are $46.3 million in Q4 2025, $53.7 million for Q3 2025, and $29.1 million during Q2 2025.